Search Icon
SNGX Archived Articles

Soligenix, Inc. (NASDAQ:SNGX): Advancing Photodynamic Therapy and Innate Defense Regulator Technology for Rare Diseases

Published on March 14, 2025

Soligenix, Inc. (NASDAQ:SNGX): Advancing Novel Therapeutics for Rare Diseases

Published on November 27, 2024

Soligenix, Inc. (NASDAQ:SNGX): Positive Interim Results for HyBryte™ in Investigator-Initiated Study in CTCL; Raising Valuation to $35 Per Share

Published on September 24, 2024